In WVC Washington’s discussion with Dr Catchpole, they gain further insight into human challenge trials and how hVIVO is aiding the community in vaccine development. hVIVO plc (formerly Open Orphan plc),

Background A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established inseronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the

Clinical trials play an important role in helping to ensure new drugs can be discovered, tested for safety and efficacy, and ultimately make their way onto the market. Over a million

The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare,

hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery and development. Their work includes assay development,

Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is

Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is

Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. The company – which tests infectious

hVIVO plc, a specialist in testing infectious and respiratory disease products using human challenge clinical trials, has reported a 16% increase in revenue for 2023 to £56m. The company, listed